

NomoCan Pharmaceuticals LLC



Downstate Biotechnology Center
760 Parkside Ave, Suite 205
Brooklyn, NY 11226

Telephone: 917-966-8610
Email: ehsan.yazdi@nomocan.com

Industry:

- Pharma
- Biotech
- Diagnostic

Management:

- Ehsan Sarafraz-Yazdi, PhD
- Josef Michl, MD
- Kamyar Neshvadian, FRM

Number of Employees: Two

Finance:

- Current Investors to Date: Multiple Angel Investors
- Amount of Financing Raised to Date: \$700K

Legal:

- Corporate: Wahab and Medenica LLC
- IP: Elaine Laflamme, Esq.

Executive Summary:

NomoCan Pharmaceuticals is a pre-clinical Limited Liability Company (LLC) registered in the state of Delaware in 2013. NomoCan Pharmaceuticals offers the first-in-kind targeted therapy for the treatment of pancreatic cancer. Our technology not only makes available a highly selective and specific diagnostic and prognostic test for early detection, but more remarkably, it introduces a highly effective monoclonal antibody (mAb) drug for the treatment of pancreatic cancer in order to bring hope to patients and families affected by this devastating lethal disease. The company is currently operating out of its laboratory in Downstate Bio-incubator, a NYS designated tax-free zone in Brooklyn, NY.

Market Opportunity:

Pancreatic Cancer is one of the most aggressive cancers with a 5-year survival of less than 6% (as compared to 89% for breast cancer). There are currently no targeted therapies available in clinic for pancreatic cancer, which affects 44,000 people annually in the US. The current market for pancreatic cancer drugs is \$165MM, which consists mostly of toxic non-specific chemotherapeutic agents. Pancreatic Cancer will become the 2nd leading cause of death for cancer patients in the U.S. Thus, there is a major unmet medical need for the development of new targeted drugs for the treatment of this devastating cancer.

Product:

NomoCan Pharmaceuticals is developing a monoclonal antibody that selectively and specifically targets and kills pancreatic cancer cells.

Commercial/Technical Milestones:

Currently NomoCan aims to humanize its mouse mAb in preparation of its pre-clinical data for submission of an Investigational New Drug (IND). Projecting forward and upon approval of the IND application by the FDA, the company will conduct Phase I-III human clinical trials in collaboration with larger oncology pharmaceutical companies.

Intellectual Property:

NomoCan is in final stages of obtaining an exclusive license for the technology from SUNY research foundation. Moreover, the company will file composition of matter patents on the human mAb, as well as other IP, which will give it a broad and defensible portfolio.

Competitive Landscape

Abraxane (Celgene) and Gemcitabine (Eli Lilly) are non-specific chemotherapeutic agents currently used in the clinic for the treatment of pancreatic cancer. Irinotecan (Marrimack) is a nano-chemo agent in clinical development. Successful development of NomoCan's highly selective and specific targeted mAb drug would be the first in its kind to be developed for pancreatic cancer. Our mAb be more effective in targeting the tumor without harming the normal cells and therefore will minimize the side effect of non-specific chemotherapeutic agents currently in the clinic or in clinical development.

Financial Projections:

NomoCan Pharmaceuticals is seeking to raise \$2.5 million for the completion of its IND-enabling studies and the submission of IND application to the FDA. To date the company has raised \$700K to advance its pre-clinical studies.